Setmelanotide is a potent MC4R agonist which displays both clinical efficacy and minimal undesirable cardiovascular effects and has proven to be a highly promising new addition to the armamentarium for personalised obesity pharmacotherapy. This evidence concerns the gene MC4R and Obesity.